lundi 21 mars 2016

Onco Actu du 21 mars 2016

4. Dépistage, diagnostic et pronostic

The Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer [Myriad]

4.2 Dép., diag. & prono. - Génome

Affymetrix Rejects $1.5 Billion Takeover Bid [NY Times]

5.2.2 Pharma - Fusions & Acquisitions

Omnis, Magnis Merge Into Vyriad, With Focus on Cancer Immunotherapies [GEN]

5.3 Traitements - FDA, EMA,...

NIH, FDA Release Streamlined Clinical Trial Protocol Template [RAPS]

EMA recommends new safety measures for Zydelig [EMA]

FDA and NIH Release a Draft Clinical Trial Protocol Template for Public Comment [FDA Voice]

5.4 Traitements - Economie

UK cost agency backs J&J cancer drug in change of heart [Reuters]

NICE recommends abiraterone for prostate cancer [NICE]

6.1 Observation

Contralateral Prophylactic Mastectomies Are Worse Than Useless for Most Breast Cancer [The Incidental Economist]

With cancer in one breast, no survival advantage in removing second one [Reuters]

6.10 Politiques

Biden to name former Gore aide as head of cancer task force [STAT]

6.11 Patients

'I nearly died in a medical drug trial' [BBC News]

‘I’m 16. Five months ago, I was diagnosed with terminal cancer’ [The Guardian]

6.6 Publications

Seven Things Every Researcher Should Know About Scholarly Publishing [The Scholarly Kitchen]

6.9 Controverses

Brigham Doc's NEJM Paper Decries Morcellation's Demise—Did She Get Confidential Patient Information? [The Cancer Letter]